Biomarkers in the Central Nervous System

2019-04-01
Price :
Published : Apr-2019
No. of Pages : 150
Table of Contents
1. Preface
1.1 Abbreviations
1.2 Related Reports
2. Executive Summary
2.1 Key Findings
2.2 KOL and Payer Insights
3. Introduction and Classification of Biomarkers
3.1 Definition of Biomarker
3.2 Type of Biomarkers
3.3 Biomarkers in CNS
3.4 KOL Perspectives
4. Biomarkers Support Technologies in CNS
4.1 Overview
4.2 Neuroimaging, Genomics and Proteomics
4.3 Epigenetic, Metabolomics and Transcriptomics
4.4 Lipidomics and Immune system
4.5 Biomarkers Diagnosis Methods in CNS
4.6 KOL Perspectives
5. Assessment of Clinical Trials Involving Biomarkers in the 8MM
5.1 Pipeline Overview 8MM
5.2 Biomarkers Trials - Top Indications in CNS in the 8MM
5.3 Clinical Trials - Leading Industry Sponsors in the 8MM
6. Indication-Specific Overview: Alzheimer's Disease
6.1 Overview
6.2 Epidemiology
6.3 Global Statistic Biomarkers in AD
6.4 Biomarkers in AD
6.5 Neuroimaging in AD
6.6 Amyloid Biomarkers
6.7 AD Biomarkers Products
6.8 CSF Amyloid Based Tests
6.9 Blood Tests
6.10 Tau Biomarkers
6.11 Genetic Biomarkers
6.12 Unmet needs and Challenges in AD Biomarkers
6.13 KOL Perspectives
7. Indication-Specific Overview: Schizophrenia
7.1 Overview
7.2 Epidemiology
7.3 Global Statistic Biomarkers in Schizophrenia
7.4 Biomarkers in Schizophrenia
7.5 Neuroimaging in Schizophrenia
7.6 Genetic and Epigenetic Biomarkers in Schizophrenia
7.7 Protein Biomarkers in Schizophrenia
7.8 Metabolic and Other Biomarkers in Schizophrenia
7.9 Unmet needs and Challenges in Schizophrenia Biomarkers
7.10 KOL Perspectives
8. Indication-Specific Overview: Multiple Sclerosis
8.1 Overview
8.2 Epidemiology
8.3 Global Statistic Biomarkers in MS
8.4 Biomarkers in MS
8.5 Diagnostic Biomarkers in MS -Neuroimaging
8.6 Diagnostic Biomarkers in MS -Intrathecal Immunoglobulin G Synthesis
8.7 Genetic Biomarkers in MS
8.8 Biomarkers to Guide Choice of Therapy
8.9 Promising Biomarkers in MS - Neurofilament Light Chain
8.10 Biomarkers in MS - Glial Pathology
8.11 Unmet needs and Challenges in MS Biomarkers
8.12 KOL Perspectives
9. Market Opportunities
9.1 Overview
9.2 Market Drivers
9.3 Market Barriers
9.4 Unmet Needs
9.5 Experts Perspectives
10. Market Access
10.1 Overview
10.2 Regulation and Reimbursement in the US
10.2.1 Payer Perspective
10.3 Regulation and Reimbursement in the EU
10.3.1 Payer Perspective
10.4 Regulation and Reimbursement in Japan
10.4.1 KOL Perspective
10.5 Regulation and Reimbursement in China
11. Market Outlook
11.1 Expert Perspectives
12. Appendix
12.1 Sources
12.2 Methodology
12.3 Primary Research
12.4 About the Authors
12.5 About GlobalData
12.6 Contact Us
Filed in: Pharmaceutical
Publisher : GlobalData